Orgaran (Danaparoid Sodium)

Danaparoid Sodium, the active ingredient in Orgaran, is a heparinoid presented as an injectable solution for intravenous infusion use. It is employed for the prophylaxis and treatment of venous thromboembolism in patients with heparin‑induced thrombocytopenia and for preventing deep‑vein thrombosis when HIT is a concern.

GNH USA supplies Orgaran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Orgaran is an anticoagulant that acts within the coagulation cascade to prevent clot formation in high‑risk settings.

- Heparin‑induced thrombocytopenia (HIT): Provides safe prophylaxis and treatment of venous thromboembolism without cross‑reactivity to heparin antibodies. - Orthopedic surgery: Prevents deep‑vein thrombosis in patients where HIT risk precludes standard heparin use. - Vascular surgery: Reduces incidence of postoperative thrombotic events in HIT‑susceptible individuals.

Adverse reactions to Danaparoid sodium may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Minor bleeding at infusion site - Hematuria - Epistaxis - Gastrointestinal bleeding - Bruising or ecchymosis - Elevated liver enzymes

Serious or Rare Side Effects: - Major hemorrhage (intracranial, gastrointestinal) - Thrombocytopenia unrelated to HIT - Hypersensitivity reactions including anaphylaxis - Disseminated intravascular coagulation (DIC) - Acute renal failure secondary to bleeding - Severe skin necrosis at infusion site

When using Orgaran, clinicians should assess patient‑specific risk factors and monitor laboratory parameters.

- Renal impairment: Adjust dosing and monitor renal function closely. - Hepatic dysfunction: Observe liver enzymes and consider dose modification. - Concomitant anticoagulants: Evaluate cumulative bleeding risk. - Recent surgery or trauma: Delay infusion until hemostasis is secured. - Pregnancy and lactation: Use only if clearly indicated after risk‑benefit evaluation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Danaparoid sodium can interact with several drug classes, influencing bleeding risk and anticoagulant effectiveness.

Major Interactions (Avoid): - Direct thrombin inhibitors (e.g., argatroban, dabigatran): combined use markedly increases bleeding risk. - Factor Xa inhibitors (e.g., rivaroxaban, apixaban): additive anticoagulant effect may lead to severe hemorrhage.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (aspirin, clopidogrel): may enhance minor bleeding. - Non‑steroidal anti‑inflamatory NSAIDs: increase gastrointestinal bleeding potential. - Glycoprotein IIb/IIIa inhibitors: monitor platelet counts and bleeding signs. - Heparin products: cross‑reactivity risk requires careful laboratory monitoring. - Vitamin K antagonists (warfarin): overlapping anticoagulation necessitates INR surveillance.